Spyre Therapeutics, Inc. (SYRE)

80.10 +1.47 (+1.87%) USD  |  NASDAQ  |  Oct 15, 16:00
80.15 +0.05 (+0.06%) After-Hours: 20:00
More

Spyre Therapeutics Cash from Operations (TTM) : -209.47M for June 30, 2026

Cash from Operations (TTM) Chart

Historical Cash from Operations (TTM) Data

View and export this data back to 2015. Start Trial.
Date Value
June 30, 2026 -209.47M
March 31, 2026 -185.87M
December 31, 2025 -169.41M
September 30, 2025 -162.30M
June 30, 2025 -154.68M
March 31, 2025 -170.36M
December 31, 2024 -157.82M
September 30, 2024 -151.32M
June 30, 2024 -156.42M
March 31, 2024 -110.82M
December 31, 2023 -99.91M
September 30, 2023 -87.01M
June 30, 2023 -67.48M
March 31, 2023 -71.52M
December 31, 2022 -80.14M
September 30, 2022 -81.27M
June 30, 2022 -83.20M
March 31, 2022 -60.45M
December 31, 2021 -53.72M
September 30, 2021 -51.58M
June 30, 2021 -52.12M
March 31, 2021 -73.61M
Date Value
December 31, 2020 -75.78M
September 30, 2020 -74.94M
June 30, 2020 -74.61M
March 31, 2020 -71.58M
December 31, 2019 -65.69M
September 30, 2019 -56.60M
June 30, 2019 -47.89M
March 31, 2019 -40.55M
December 31, 2018 -32.19M
September 30, 2018 -30.87M
June 30, 2018 -29.73M
March 31, 2018 -26.63M
December 31, 2017 -24.62M
September 30, 2017 -23.10M
June 30, 2017 -21.59M
March 31, 2017 -20.28M
December 31, 2016 -18.84M
September 30, 2016 -15.32M
June 30, 2016 -13.26M
March 31, 2016 -12.49M
December 31, 2015 -10.98M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
AbbVie, Inc. 19.51B
Incyte Corp. 1.980B
SELLAS Life Sciences Group, Inc. -28.42M
Relay Therapeutics, Inc. -212.20M
ACADIA Pharmaceuticals, Inc. 160.32M